GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

This study is testing a chemotherapy combination called GVM (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin), with or without rituximab (an antibody targeting CD20), in people with aggressive non-Hodgkin lymphoma (NHL) that has come back after previous treatment or did not respond to prior therapy. **You may be eligible if...** - You are between 18 and 65 years old - You have aggressive non-Hodgkin lymphoma that has relapsed (came back after a response lasting more than 6 months) or is refractory (never responded, or responded for less than 6 months) - You have already received at least one prior standard treatment - Your expected survival is at least 3 months - Your liver, kidneys, and blood counts meet the minimum requirements **You may NOT be eligible if...** - You have active brain lymphoma involvement - You have had a prior stem cell transplant using donor cells (allogeneic transplant) - You have serious uncontrolled infections or active hepatitis B or C - You have a severe autoimmune condition requiring long-term steroids - You have a serious heart condition including uncontrolled arrhythmia or heart failure Talk to your doctor to see if this trial is right for you.